psilocybina ˌsaɪləˈsaɪbɪn syləsybin ˌsɪl naturally occurring psychedelic prodrug compound produced species fungi potent members genus psilocybe p azurescens p semilanceata p cyanescens psilocybin also isolated dozen genera psilocybin biologically inactive quickly converted body psilocin mindaltering effects similar aspects lysergic acid diethylamide lsd mescaline dimethyltryptamine dmt general effects include euphoria visual mental hallucinations changes perception distorted sense time perceived spiritual experiences also cause adverse reactions nausea panic attacks imagery found cave paintings rock art modernday spain algeria suggests human use psilocybin mushrooms predates recorded history mesoamerica mushrooms long consumed spiritual divinatory ceremonies spanish chroniclers first documented use sixteenth century swiss chemist albert hofmann isolated psilocybin psilocin mushroom psilocybe mexicana hofmanns employer sandoz marketed sold pure psilocybin physicians clinicians worldwide use psychedelic therapy although increasingly restrictive drug laws curbed scientific research effects psilocybin hallucinogens popularity entheogen spiritualityenhancing agent grew next decade owing largely increased availability information cultivate psilocybin mushrooms intensity duration effects psilocybin variable depending species cultivar mushrooms dosage individual physiology set setting shown experiments led timothy leary harvard university early ingested psilocybin rapidly metabolized psilocin acts serotonin receptors brain mindaltering effects psilocybin typically last two six hours although individuals influence psilocybin effects may seem last much longer since drug distort perception time possession psilocybincontaining mushrooms outlawed countries psilocybin classified schedule controlled substance united nations convention psychotropic substances effects psilocybin highly variable depend mindset environment user experience factors commonly referred set setting early timothy leary colleagues harvard university investigated role set setting effects psilocybin administered drug volunteers various backgrounds environment intended similar comfortable living room subjects given questionnaires assess experiences contribution background situational factors individuals experience psilocybin prior study reported pleasant experiences drug novel group size dosage preparation expectancy important determinants drug response general groups eight felt groups less supportive experiences less pleasant conversely smaller groups fewer six seen supportive reported positive reactions drug groups leary colleagues proposed psilocybin heightens suggestibility making individual receptive interpersonal interactions environmental findings affirmed later review jos ten berge concluded dosage set setting fundamental factors determining outcome experiments tested effects psychedelic drugs artists ingesting psilocybin wide range subjective effects may experienced feelings disorientation lethargy giddiness euphoria joy depression one study volunteers given high dose reported feelings significant fear experienced transient studies johns hopkins among given moderate dose still enough give high probability profound beneficial experience negative experiences rare whereas onethird given high dose experienced anxiety low doses induce hallucinatory effects closedeye hallucinations may occur affected individual sees multicolored geometric shapes vivid imaginative individuals report synesthesia tactile sensations viewing higher doses psilocybin lead intensification affective responses enhanced ability introspection regression primitive childlike thinking activation vivid memory traces pronounced emotional openeye visual hallucinations common may detailed although rarely confused prospective study roland r griffiths colleagues suggests single high dosage psilocybin cause longterm changes personality users half study healthy spiritually active many possessing postgraduate increase personality dimension openness assessed using revised neo personality inventory positive effect apparent year psilocybin session according study authors finding significant study prospectively demonstrated personality change healthy adults experimentally manipulated discrete study griffiths found doses psilocybin inducing mysticaltype experiences brought lasting changes traits including altruism gratitude forgiveness feeling close others combined regular meditation practice extensive spiritual practice support although researchers described instances psychedelic drug usage leading new psychological understandings personal known whether experimental results generalized larger common responses include pupil dilation changes heart rate including increases decreases variable responses changes blood pressure including hypotension hypertension general instability changes stretch reflex including increases decreases nausea tremor dysmetria inability properly direct limit motionsb temporary increases blood pressure caused drug risk factor users preexisting qualitative somatic effects caused psilocybin corroborated several early clinical magazine survey clubgoers uk found nausea vomiting experienced quarter used psilocybin mushrooms last year although effect caused mushroom rather psilocybin one study administration gradually increasing dosages psilocybin daily days measurable effect electrolyte levels blood sugar levels liver toxicity psilocybin known strongly influence subjective experience passage users often feel time slowed resulting perception minutes appear hours time standing studies demonstrated psilocybin significantly impairs subjects ability gauge time intervals longer seconds impairs ability synchronize interbeat intervals longer seconds reduces preferred tapping results consistent drugs role affecting prefrontal cortex role prefrontal cortex known play time however neurochemical basis psilocybins effects perception time known users pleasant experience feel sense connection others nature universe perceptions emotions also often intensified users unpleasant experience bad trip describe reaction accompanied fear unpleasant feelings occasionally dangerous behavior general phrase bad trip used describe reaction characterized primarily fear unpleasant emotions transitory experience feelings variety factors may contribute psilocybin user experiencing bad trip including tripping emotional physical low nonsupportive environment see set setting ingesting psilocybin combination drugs including alcohol also increase likelihood bad duration experience effects psilocybin similar comparable dosages lysergic acid diethylamide lsd mescaline however psychedelics encyclopedia author peter stafford noted psilocybin experience seems warmer forceful less isolating tends build connections people generally much communication use anthropological studies regarding personal psychosocial effects psilocybin seen many traditional societies powerful mindactive substances psilocybin regularly consumed ritually therapeutic purposes transcending normal everyday positive effects psilocybin individuals observed taking anthropological approach moving away western biomedical society aided studies done within certain traditional societies use psilocybin frequent shamanic healing rituals group collectives praise guide healer shaman helping alleviate pains aches hurt group ritual practice participants guide ingests psilocybin help extract toxic psychic residues sorcerous found ones body group therapies using classic psychedelics becoming commonly used western world clinical practice may continue grow long providing evidence remains indicative safety social sense group shaped experiences surrounding psilocybin view plant collectively mentioned anthropology group partakes journey together thus adding spiritual social body roles hierarchies gender subjectively psilocybin mushrooms continue used indigenous new world cultures religious divinatory spiritual contexts reflecting meaning word entheogen god within mushrooms revered powerful spiritual sacraments provide access sacred worlds typically used small group community settings enhance group cohesion reaffirm traditional terence mckenna documented worldwide practices psilocybin mushroom usage part cultural ethos relating earth mysteries nature suggested mushrooms enhanced selfawareness sense contact transcendent deeper understanding connectedness psychedelic drugs induce states consciousness lasting personal meaning spiritual significance individuals religious spiritually inclined states called mystical experiences scholars proposed many qualities druginduced mystical experience indistinguishable mystical experiences achieved nondrug techniques meditation holotropic walter pahnke colleagues systematically evaluated mystical experiences called mystical consciousness categorizing common features categories according pahnke describe core universal psychological experience free culturally determined philosophical theological interpretations allow researchers assess mystical experiences qualitative numerical marsh chapel experiment run pahnke harvard divinity school supervision timothy almost graduate degree divinity student volunteers received psilocybin reported profound religious one participants religious scholar huston smith author several textbooks comparative religion later described experience powerful cosmic homecoming ever followup experiment subjects given psilocybin described experience elements genuine mystical nature characterized one high points spiritual psychedelic researcher rick doblin considered study partially flawed due incorrect implementation doubleblind procedure several imprecise questions mystical experience questionnaire nevertheless said study cast considerable doubt assertion mystical experiences catalyzed drugs way inferior nondrug mystical experiences immediate content longterm sentiment echoed psychiatrist william richards review stated psychedelic mushroom use may constitute one technology evoking revelatory experiences similar identical occur socalled spontaneous alterations brain group researchers johns hopkins school medicine led roland griffiths conducted study assess immediate longterm psychological effects psilocybin experience using modified version mystical experience questionnaire rigorous doubleblind asked interview similarity work learys griffiths explained difference conducting rigorous systematic research psilocybin carefully monitored conditions route dr leary abandoned early national institute drug abusefunded study published praised experts soundness experimental designc experiment volunteers without prior experience hallucinogens given psilocybin methylphenidate ritalin separate sessions methylphenidate sessions served control psychoactive placebo degree mystical experience measured using questionnaire developed ralph w subjects reported complete mystical experience psilocybin session reported outcome experience methylphenidate two months taking psilocybin participants reported moderately greatly increased life satisfaction sense wellbeing participants also strong extreme experience fear dysphoria ie bad trip point psilocybin session reported subject methylphenidate session onethird total reported dysphoria dominated entire session negative effects reported easily managed researchers lasting negative effect subjects sense followup study conducted months original psilocybin session confirmed participants continued attribute deep personal meaning experience almost onethird subjects reported experience single meaningful spiritually significant event lives twothirds reported among five spiritually significant events twothirds indicated experience increased sense wellbeing life even months reported mystical experiences scored average percentage points higher personality trait opennessintellect personality traits normally stable across lifespan adults likewise recent webbased questionnaire study designed investigate user perceptions benefits harms hallucinogenic drug use psilocybin users reported use psilocybin longterm positive impact sense many recent studies concluded psilocybin cause mysticaltype experiences substantial sustained personal meaning spiritual significance medical community agree paul r mchugh formerly director department psychiatry behavioral science johns hopkins responded follows book review unmentioned fact harvard psychedelic club lsd psilocybin mescaline like produce higher consciousness rather particular kind lower consciousness known well psychiatrists toxic although psilocybin may prepared synthetically outside research setting typically used form psilocybin present certain species mushrooms ingested several ways consuming fresh dried fruit bodies preparing herbal tea combining foods mask bitter rare cases people injected mushroom extracts comparatively fatal incidents reported literature associated psychedelic mushroom usage involve simultaneous use drugs especially alcohol probably common cause hospital admissions resulting psychedelic mushroom usage involves bad trips panic reactions affected individuals become extremely anxious confused agitated disoriented accidents selfinjury suicide attempts result serious cases acute psychotic although studies linked psilocybin birth recommended pregnant women avoid data sparse decade leading increasing number psilocybin mushroom overdoses recorded nonetheless number events requiring hospitalization remain rare overdoses generally mild selflimiting review regarding management psychedelic overdoses suggested psilocybin related overdose management prioritize managing immediate adverse effects anxiety paranoia rather specific pharmacological interventions physiological toxicity tends rather one analysis mushrooms used people hospitalized psilocybin poisoning found high concentrations phenethylamine pea also detected urine people used psilocybin mushrooms hypothesized pea may intensify effect psilocybin rats median lethal dose administered orally milligrams per kilogram mgkg approximately one half times caffeine administered intravenously rabbits psilocybins approximately psilocybin comprises approximately weight psilocybe cubensis mushrooms nearly kilograms lb dried mushrooms kilograms lb fresh mushrooms would required lb person reach mgkg value based results animal studies lethal dose psilocybin extrapolated grams times greater effective dose registry toxic effects chemical substances assigns psilocybin relatively high therapeutic index higher values correspond better safety profile comparison therapeutic indices aspirin nicotine lethal dose psilocybin toxicity alone unknown rarely two cases attributed overdosing hallucinogenic mushrooms without concurrent use drugs reported scientific literature may involve factors aside panic reactions occur consumption psilocybincontaining mushrooms especially ingestion accidental otherwise unexpected reactions characterized violent behavior suicidal schizophrenialike reported literature survey conducted united kingdom found almost quarter used psilocybin mushrooms past year experienced panic verification adverse effects less frequently reported include paranoia confusion prolonged derealization disconnection reality psilocybin usage temporarily induce state depersonalization usage schizophrenia induce acute psychotic states requiring similarity psilocybininduced symptoms schizophrenia made drug useful research tool behavioral neuroimaging studies psychotic cases psychotic symptoms thought arise deficient gating sensory cognitive information brain ultimately lead cognitive fragmentation flashbacks spontaneous recurrences previous psilocybin experience occur long used psilocybin mushrooms hallucinogen persisting perception disorder hppd characterized continual presence visual disturbances similar generated psychedelic substances neither flashbacks hppd commonly associated psilocybin correlations hppd psychedelics obscured polydrug use tolerance psilocybin builds dissipates quickly ingesting psilocybin week lead diminished effects tolerance dissipates days doses spaced several days apart avoid crosstolerance develop psilocybin pharmacologically similar psilocybin phenethylamines mescaline repeated use psilocybin lead physical study concluded based us data period adolescentonset defined ages usage hallucinogenic drugs including psilocybin increase risk drug dependence adulthood contrast adolescent usage cannabis cocaine inhalants anxiolytic medicines stimulants associated excess risk developing clinical features associated drug likewise dutch study ranked relative harm psilocybin mushrooms compared selection recreational drugs including alcohol cannabis cocaine ecstasy heroin tobacco psilocybin mushrooms ranked illicit drug lowest corroborating conclusions reached earlier expert groups united psilocybin naturallyoccurring substituted tryptamine features indole ring linked aminoethyl substituent structurally related serotonin monoamine neurotransmitter derivative amino acid tryptophan psilocybin member general class tryptophanbased compounds originally functioned antioxidants earlier life forms assuming complex functions multicellular organisms including related indolecontaining psychedelic compounds include dimethyltryptamine found many plant species trace amounts mammals bufotenin found skin certain amphibians especially colorado river psilocybin white crystalline solid soluble water methanol ethanol insoluble nonpolar organic solvents chloroform petroleum melting point ammonialike pka values estimated two successive phosphate hydroxy groups dimethylamine nitrogen typically exists zwitterionic two known crystalline polymorphs psilocybin well reported hydrated psilocybin rapidly oxidizes upon exposure important consideration using analytical albert hofmann et al first team synthesize psilocybin since time various chemists improved methods laboratory synthesis purification psilocybin particular shirota et al reported novel method synthesis psilocybin gram scale require chromatographic purification fricke et al described enzymatic pathway synthesis psilocybin psilocin publishing results sherwood et al significantly improved upon shirotas method producing kilogram scale employing less expensive reagents publishing results isotopic labeling experiments suggested biosynthesis psilocybin fourstep recent research demonstrated least p fact third step neither dimethyltryptamine psilocin sequence intermediate steps shown involve four enzymes psid psih psik psim p cubensis p cyanescens although possible biosynthetic pathway differs enzymes encoded gene clusters psilocybe panaeolus escherichia coli genetically modified manufacture large amounts psilocybin produced de novo gm psilocybin refers compound capable promoting rapid sustained neuroplasticity psilocybin rapidly dephosphorylated body psilocin agonist several serotonin receptors also known receptors rats psilocin binds high affinity receptors low affinity receptors including effects also mediated via psychotomimetic psychosismimicking effects psilocin blocked dosedependent fashion antagonist drug various lines evidence shown interactions receptors also contribute subjective behavioral effects example psilocin indirectly increases concentration neurotransmitter dopamine basal ganglia psychotomimetic symptoms psilocin reduced haloperidol nonselective dopamine receptor antagonist taken together suggest may indirect dopaminergic contribution psilocins psychotomimetic psilocybin psilocin affinity dopamine receptor unlike another common receptor agonist lysergic acid diethylamide psilocin antagonizes receptors moderate affinity compared lsd lower serotonin receptors located numerous parts brain including cerebral cortex involved wide range functions including regulation mood motivation body temperature appetite psilocybin induces regiondependent alterations glutamate may associated subjective experiences ego effects drug begin minutes ingestion last hours depending dose species individual half life psilocybin minutes taken orally minutes injected psilocybin metabolized mostly liver becomes converted psilocin undergoes firstpass effect whereby concentration greatly reduced reaches systemic circulation psilocin broken enzyme monoamine oxidase produce several metabolites circulate blood plasma including psilocin broken enzymes instead forms glucuronide biochemical mechanism animals use eliminate substances linking glucuronic acid excreted psilocin glucuronated glucuronosyltransferase enzymes liver small based studies using animals ingested psilocybin absorbed stomach intestine within hours absorbed psilocybin excreted urine excreted bile feces although remaining drug eliminated way within hours still detectable urine clinical studies show psilocin concentrations plasma adults average μgliter within hours ingestion single mg oral psilocybin psychological effects occur blood plasma concentration psilocybin approximately potency lsd weight per weight basis physiological effects last half monoamine oxidase inhibitors maoi known prolong enhance effects dmt one study assumed effect psilocybin would similar since structural analogue alcohol consumption may enhance effects psilocybin acetaldehyde one primary breakdown metabolites consumed alcohol reacts biogenic amines present body produce maois related tetrahydroisoquinoline tobacco smokers may also experience powerful effects tobacco smoke exposure decreases activity mao brain peripheral several relatively simple chemical available reagent testing used assess presence psilocybin extracts prepared mushrooms drug reacts marquis test produce yellow color green color mandelin neither tests however specific psilocybin example marquis test react many classes controlled drugs containing primary amino groups unsubstituted benzene rings including amphetamine ehrlichs reagent dmaca reagent used chemical sprays detect drug thin layer many modern techniques analytical chemistry used quantify psilocybin levels mushroom samples although earliest methods commonly used gas chromatography high temperature required vaporize psilocybin sample prior analysis causes spontaneously lose phosphoryl group become difficult chemically discriminate two drugs forensic toxicology techniques involving gas chromatography coupled mass spectrometry widely used due high sensitivity ability separate compounds complex biological techniques include ion mobility capillary zone ultraviolet infrared highperformance liquid chromatography hplc used electrospray mass spectrometric detection various chromatographic methods developed detect psilocin body fluids rapid emergency drug identification system remedi hs drug screening method based hplc electrochemical liquid chromatography coupled mass although determination psilocin levels urine performed without sample cleanup ie removing potential contaminants make difficult accurately assess concentration analysis plasma serum requires preliminary extraction followed derivatization extracts case specific immunoassay also developed detect psilocin whole blood publication reported using hplc quickly separate forensically important illicit drugs including psilocybin psilocin identifiable within half minute analysis analytical techniques determine psilocybin concentrations body fluids however routinely available typically used clinical psilocybin present varying concentrations species basidiomycota mushrooms review worldwide distribution hallucinogenic mushrooms gastón guzmán colleagues considered distributed amongst following genera psilocybe species gymnopilus panaeolus copelandia hypholoma pluteus inocybe conocybe panaeolina gerronema galerina guzmán increased estimate number psilocybincontaining psilocybe species review majority found mexico species remainder distributed united states canada europe asia africa australia associated islands diversity psilocybin mushrooms reported increased horizontal transfer psilocybin gene cluster unrelated mushroom general psilocybincontaining species darkspored gilled mushrooms grow meadows woods subtropics tropics usually soils rich humus plant psilocybin mushrooms occur continents majority species found subtropical humid psilocybe species commonly found tropics include p cubensis p subcubensis p guzmán worlds widely distributed psilocybin found europe north america asia south america australia new zealand entirely absent although presence absence psilocybin much use chemotaxonomical marker familial level higher used classify taxa lower taxonomic caps stems contain psychoactive compounds although caps consistently contain spores mushrooms contain psilocybin total potency varies greatly species even specimens species collected grown psilocybin biosynthesis occurs early formation fruit bodies sclerotia younger smaller mushrooms tend higher concentration drug larger mature general psilocybin content mushrooms quite variable ranging almost nothing dry depends species strain growth drying conditions mushroom cultivated mushrooms less variability psilocybin content wild drug stable dried fresh mushrooms dried mushrooms retain potency months even mushrooms stored fresh four weeks contain traces original psilocybin contents dried herbarium specimens psilocybe semilanceata one study shown decrease increasing age sample collections dated years old contained dry weight mature mycelia contain psilocybin young mycelia recently germinated spores lack appreciable many species mushrooms containing psilocybin also contain lesser amounts analog compounds baeocystin chemicals thought biogenic although species psilocybincontaining mushrooms bruise blue handled damaged due oxidization phenolic compounds reaction definitive method identification determining mushrooms evidence suggest psychoactive mushrooms used humans religious ceremonies thousands years pictographs discovered near spanish town villar del humo illustrate several mushrooms tentatively identified psilocybe hispanica hallucinogenic species native rock art also discovered tassili algeria believed depict psychedelic mushrooms transformation user influence paintings said date back archaeological artifacts mexico well socalled mayan mushroom stones guatemala also interpreted scholars evidence ritual ceremonial usage psychoactive mushrooms mayan aztec cultures nahuatl language aztecs mushrooms called teonanácatl gods flesh following arrival spanish explorers new world sixteenth century chroniclers reported use mushrooms natives ceremonial religious purposes according dominican friar diego durán history indies new spain published c mushrooms eaten festivities conducted occasion accession throne aztec emperor moctezuma ii franciscan friar bernardino de sahagún wrote witnessing mushroom usage florentine codex published described merchants would celebrate upon returning successful business trip consuming mushrooms evoke revelatory defeat aztecs spanish forbade traditional religious practices rituals considered pagan idolatry including ceremonial mushroom use next four centuries indians mesoamerica hid use entheogens spanish although dozens species psychedelic mushrooms found europe little documented usage species old world history besides use amanita muscaria among siberian existing historical accounts psilocybin mushrooms typically lack sufficient information allow species identification usually refer nature effects example flemish botanist carolus clusius described bolond gomba crazy mushroom used rural hungary prepare love potions english botanist john parkinson included details foolish mushroom herbal theatricum first reliably documented report intoxication psilocybe common widespread psychedelic british family prepared meal mushrooms picked londons green american banker amateur ethnomycologist r gordon wasson wife valentina p wasson physician studied ritual use psychoactive mushrooms native population mazatec village huautla de jiménez mexico wasson described psychedelic visions experienced rituals seeking magic mushroom article published popular american weekly life later year accompanied followup expedition french mycologist roger heim identified several mushrooms psilocybe heim cultivated mushrooms france sent samples analysis albert hofmann chemist employed swiss pharmaceutical company sandoz novartis synthesized lysergic acid diethylamide lsd research group isolated identified psychoactive alkaloids psilocybin psilocin psilocybe mexicana publishing results team aided discovery process hofmanns willingness ingest mushroom extracts help verify presence active next hofmanns team synthesized several structural analogs compounds examine structural changes would affect psychoactivity research led development ethocybin physiological effects compounds last three half hours half long psilocybin proved manageable latter use psycholytic sandoz also marketed sold pure psilocybin name indocybin clinicians researchers reports serious complications psilocybin used early harvard university became testing ground psilocybin efforts timothy leary associates ralph metzner richard alpert later changed name ram dass leary obtained synthesized psilocybin hofmann sandoz pharmaceuticals studies concord prison experiment suggested promising results using psilocybin clinical according review safety guidelines human hallucinogenic research however leary alperts wellpublicized termination harvard later advocacy hallucinogen use undermined objective scientific approach studying response concerns increase unauthorized use psychedelic drugs general public psilocybin hallucinogenic drugs suffered negative press faced increasingly restrictive laws united states laws passed prohibited production trade ingestion hallucinogenic drugs sandoz stopped producing lsd psilocybin congress passed federal comprehensive drug abuse prevention control act made lsd peyote psilocybin hallucinogens illegal use purposes including scientific united states politicians agenda lsd usage swept psilocybin along schedule category illicit drugs restrictions use drugs human research made funding projects difficult obtain globally scientists worked psychedelic drugs faced professionally although hofmann tested compounds never advocated legalization medical use book lsd mein sorgenkind lsd problem child hofmann described problematic use hallucinogens despite legal restrictions psilocybin use witnessed emergence psilocybin entheogen due large part wide dissemination information topic included works author carlos castaneda several books taught technique growing psilocybin mushrooms one popular latter group published pseudonyms ot oss oeric jeremy bigwood dennis j mckenna k harrison mckenna terence mckenna entitled psilocybin magic mushroom growers guide copies sold ethnobiologist jonathan ott explains authors adapted san antonios technique producing edible mushrooms casing mycelial cultures rye grain substrate san antonio production psilocybe stropharia cubensis new technique involved use ordinary kitchen implements first time layperson able produce potent entheogen home without access sophisticated technology equipment chemical san antonios technique describes method grow common edible mushroom agaricus lack clarity laws psilocybin mushrooms specifically form sclerotia also known truffles european retailers late early commercialized marketed smartshops netherlands uk online several websitesf emerged contributed accessibility information description use effects exchange experiences among users since six eu countries tightened legislation psilocybin mushrooms response concerns prevalence increasing hallucinogens effects human consciousness subject scientific study particularly europe advances neuropharmacology neuropsychology availability brain imaging techniques provided impetus using drugs like psilocybin probe neural underpinnings psychotic symptom formation including ego disorders recent studies united states attracted attention popular press thrust psilocybin back legal status unauthorised actions psilocybin mushrooms varies worldwide psilocybin psilocin listed schedule drugs united nations convention psychotropic schedule drugs defined drugs high potential abuse drugs recognized medical uses however psilocybin mushrooms numerous religious uses dozens cultures throughout history significantly lower potential abuse schedule psilocybin mushrooms regulated un many countries however level regulation prohibition psilocybin mushrooms example us psychotropic substances act uk misuse drugs act canadian controlled drugs substances act despite illegal many typically western countries uk australia us states less conservative governments opt nurture legal use psilocybin psychedelic drugs amsterdam netherlands authorities provide education promotion safe use psychedelic drugs psilocybin aim reduce public similarly religious groups like americas uniao vegetal use psychedelics traditional july australian medicines regulator permitted psychiatrists prescribe psilocybin therapeutic treatment posttraumatic stress advocates legalization argue lack evidence potential use treating certain mental health conditions research difficult conduct legal status psychoactive advocates legalization also promote utility ego argue bans cultural discrimination traditional national survey drug use us department health human services concluded number firsttime psilocybin mushroom users united states roughly equivalent number firsttime users european countries lifetime prevalence estimates psychedelic mushroom usage among young adults years range modern mexico traditional ceremonial use survives among several indigenous groups including nahuas matlatzinca totonacs mazatecs mixes zapotecs chatino although hallucinogenic psilocybe species abundant lowlying areas mexico ceremonial use takes places mountainous areas elevations greater meters ft guzmán suggests vestige spanish colonial influence several hundred years earlier mushroom use persecuted catholic psilocybin subject clinical research since early harvard psilocybin project evaluated potential value psilocybin treatment certain personality beginning psilocybin investigated possible role treatment nicotine dependence alcohol dependence disorder ocd cluster headache cancerrelated existential anxiety disorders certain mood united states food drug administration fda granted breakthrough therapy designation psilocybinassisted therapy treatmentresistant systematic review published found use psilocybin pharmaceutical substance associated reduced intensity depression role psilocybin possible psychoplastogen also httpsenwikipediaorgwikipsilocybin